How to initiate, titrate, and intensify insulin treatment in type 2 diabetes

U.S. Pharmacist

Volumn 32, Issue 10, 2007, Pages 10-16

  Triplitt, Curtis ^a,b  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; HUMAN INSULIN; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; PROTAMINE; RECOMBINANT HUMAN INSULIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ADD ON THERAPY; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES EDUCATION; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG PACKAGING; DRUG RELEASE; DRUG SAFETY; DRUG STORAGE; EVENING DOSAGE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; MEDICATION ERROR; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PATIENT SELECTION; PHARMACIST ATTITUDE; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

EID: 47749146928     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (40)

1. Centers for Disease Control. National diabetes fact sheet. United States, 2005: general information. Available at: http://www.cdc.gov/ diabetes/pubs/pdf/ndfs_2005.pdf. Accessed March 30, 2007.
2. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
3. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
4. Stratton IM, Adler AI, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
5. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care. 2007;30(suppl 1):S4-S41.
6. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(suppl 3):S16-S21.
7. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787-835.
8. Monnier L, Colette C, et al. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006;12 (suppl 1):42-46.
9. Hirsch IB, Bergenstal RM, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23:78-86.
10. Alvarsson M, Sundkvist G, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 2003;26:2231-2237.
11. Royal College of Nursing. Starting insulin treatment in adults with type 2 diabetes. Available at: www.library.nhs.uk/guidelinesfinder/ ViewResource.aspx?resID=57582. Accessed March 30, 2007.
12. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32:9S-18S.
13. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther. 2005;27:1113-1125.
14. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70:489-500.
15. Dailey G. A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy. Formulary. 2005;40:114-130.
16. Nathan DM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
17. Lilley SH, Levine GI. Management of hospitalized patients with type 2 diabetes mellitus. Am Fam Physician. 1998;57: 1079-1088.
18. American Society of Health-System Pharmacists. Antidiabetic agents. In: American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2006:3072-3149.
19. Triplitt CL, Reasner CA, Isley WL. Pharmacotherapy: A Pathophysiologic Approach. 6th ed. New York: McGraw Hill; 2005:1345.
20. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm. 2005;62:1359-1364.
21. Davidson MB, Mehta AE, Siraj ES. Inhaled human insulin: an inspiration for patients with diabetes mellitus? Cleve Clin J Med. 2006;73:569-578.
22. Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am. 2005;34:77-98.
23. Hermansen K, Davies M, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
24. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352: 174-183.
25. Brunton S, Carmichael B, et al. Type 2 diabetes: the role of insulin. J Fam Pract. 2005;54(suppl 5):445-451.
26. Rave K, Bott S, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28:1077-1082.
27. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26: 3080-3086.
28. Siebenhofer A, Plank J, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2004; CD003287.
29. Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007;13:260-268.
30. Texas Department of State Health Services. Insulin algorithm for type 2 diabetes mellitus in children and adults. Publication #45-11647. Available at: http://www.dshs.state.tx.us/diabetes/PDF/algorithms/ INST2.pdf. Accessed March 30, 2007.
31. Raskin P. Can glycemic targets be achieved - in particular with two daily injections of a mix of intermediate- and short-acting insulin? Endocr Pract. 2006;12(suppl 1):52-54.
32. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24(4):758-767.
33. Rosenstock J, Davies M, et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes. 2006;55(suppl 1)A132. Abstract.
34. Malone JK, Bai S, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005;22:374-381.
35. Raskin P, Allen E, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
36. Garber AJ, Wahlen J, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab. 2006;8:58-66.
37. Liebl A, Prager R, et al. Biphasic insulin aspart 30 (BlAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: the PREFER study. Diabetes. 2006;55(suppl 1)A123. Abstract.
38. Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technol Ther. 2005;7:620-626.
39. Paparella S. Avoiding errors with insulin therapy. J Emerg Nurs. 2006;32:325-328.
40. Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherepy. 2006;26:360-374